Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.

Mitochondria play leading roles in initiation and progression of colorectal cancer (CRC). Proteogenomic analyses of mitochondria of CRC tumor cells would likely enhance our understanding of CRC pathogenesis and reveal new independent prognostic factors and treatment targets. However, comprehensive investigations focused on mitochondria of CRC patients are lacking. Here, we investigated global profiles of structural variants, DNA methylation, chromatin accessibility, transcriptome, proteome, and phosphoproteome on human CRC. Proteomic investigations uncovered greatly diminished mitochondrial proteome size in CRC relative to that found in adjacent healthy tissues. Integrated with analysis of RNA-Seq datasets obtained from the public database containing mRNA data of 538 CRC patients, the proteomic analysis indicated that proteins encoded by 45.5% of identified prognostic CRC genes were located within mitochondria, highlighting the association between altered mitochondrial function and CRC. Subsequently, we compared structural variants, DNA methylation, and chromatin accessibility of differentially expressed genes and found that chromatin accessibility was an important factor underlying mitochondrial gene expression. Furthermore, phosphoproteomic profiling demonstrated decreased phosphorylation of most mitochondria-related kinases within CRC versus adjacent healthy tissues, while also highlighting MKK3/p38 as an essential mitochondrial regulatory pathway. Meanwhile, systems-based analyses revealed identities of key kinases, transcriptional factors, and their interconnections. This research uncovered a close relationship between mitochondrial dysfunction and poor CRC prognosis, improve our understanding of molecular mechanism underlying mitochondrial linked to human CRC, and facilitate identifies of clinically relevant CRC prognostic factors and drug targets.

[1]  V. Treviño,et al.  A systematic review of genes affecting mitochondrial processes in cancer. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[2]  D. Calvisi,et al.  Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies , 2020, Hepatology.

[3]  Long-Sen Chang,et al.  Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells. , 2020, Toxicology and applied pharmacology.

[4]  D. Turnbull,et al.  Mitochondrial Diseases: Hope for the Future , 2020, Cell.

[5]  Lijuan Wang,et al.  A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice , 2020, Gut.

[6]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[7]  M. Karin,et al.  Immunotherapy, Inflammation and Colorectal Cancer , 2020, Cells.

[8]  Georgia Theocharopoulou The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases , 2020, AIMS neuroscience.

[9]  J. Haybaeck,et al.  The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer , 2020, Cancers.

[10]  Prakash Kulkarni,et al.  The Mitochondrion as an Emerging Therapeutic Target in Cancer. , 2020, Trends in molecular medicine.

[11]  V. Jain,et al.  PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. , 2019, Drug discovery today.

[12]  S. Kalinin,et al.  Phospho-mTOR expression in human glioblastoma microglia-macrophage cells , 2019, Neurochemistry International.

[13]  A. K. Murugan mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.

[14]  A. Hadjinicolaou,et al.  Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer , 2019, Medical sciences.

[15]  Z. Stadler,et al.  Immunotherapy in colorectal cancer: rationale, challenges and potential , 2019, Nature Reviews Gastroenterology & Hepatology.

[16]  Subha Madhavan,et al.  Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities , 2019, Cell.

[17]  A. Theiss,et al.  Gut bacteria signaling to mitochondria in intestinal inflammation and cancer , 2019, Gut microbes.

[18]  N. Zahr,et al.  Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation , 2019, Drug Safety.

[19]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[20]  S. Shen-Orr,et al.  Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response , 2019, Nature Communications.

[21]  Melvin A. Park,et al.  Online Parallel Accumulation–Serial Fragmentation (PASEF) with a Novel Trapped Ion Mobility Mass Spectrometer* , 2018, Molecular & Cellular Proteomics.

[22]  C. Serrano,et al.  mTORC1 Prevents Epithelial Damage During Inflammation and Inhibits Colitis-Associated Colorectal Cancer Development , 2018, Translational oncology.

[23]  A. Mammoto,et al.  YAP1-TEAD1 signaling controls angiogenesis and mitochondrial biogenesis through PGC1α. , 2018, Microvascular research.

[24]  Ja Hyun Koo,et al.  Interplay between YAP/TAZ and Metabolism. , 2018, Cell metabolism.

[25]  Marc J. Williams,et al.  Evolutionary history of human colitis-associated colorectal cancer , 2018, Gut.

[26]  G. Bossi,et al.  Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer , 2018, Cancers.

[27]  S. Rodríguez-Perales,et al.  mTORC1 Inactivation Promotes Colitis-Induced Colorectal Cancer but Protects from APC Loss-Dependent Tumorigenesis. , 2018, Cell metabolism.

[28]  Haiyan Tan,et al.  Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation , 2017, Immunity.

[29]  M. Haigis,et al.  Mitochondria and Cancer , 2016, Cell.

[30]  B. Viollet,et al.  AMPK maintains energy homeostasis and survival in cancer cells via regulating p38/PGC-1α-mediated mitochondrial biogenesis , 2015, Cell Death Discovery.

[31]  Yingfu Li,et al.  Optimized mixture of As, Cd and Pb induce mitochondria-mediated apoptosis in C6-glioma via astroglial activation, inflammation and P38-MAPK. , 2015, American journal of cancer research.

[32]  T. Jacques,et al.  Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission , 2015, Brain : a journal of neurology.

[33]  Patty J. Lee,et al.  MKK3 mediates inflammatory response through modulation of mitochondrial function. , 2015, Free radical biology & medicine.

[34]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[35]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[36]  C. Simone,et al.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. , 2014, World journal of gastroenterology.

[37]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[38]  M. Karin,et al.  Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. , 2014, Cell metabolism.

[39]  G. Gores,et al.  The mTOR pathway in hepatic malignancies , 2013, Hepatology.

[40]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[41]  C. Eng,et al.  The promise of mTOR inhibitors in the treatment of colorectal cancer , 2012, Expert opinion on investigational drugs.

[42]  Jeffrey W. Clark,et al.  Phase 1/2 study of everolimus in advanced hepatocellular carcinoma , 2011, Cancer.

[43]  Petr Ježek,et al.  Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. , 2011, The international journal of biochemistry & cell biology.

[44]  Kathryn G. Foster,et al.  Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony* , 2010, The Journal of Biological Chemistry.

[45]  Kathryn G. Foster,et al.  Regulation of mTOR Complex 1 (mTORC1) by Raptor Ser863 and Multisite Phosphorylation* , 2009, The Journal of Biological Chemistry.

[46]  T. Sturgill,et al.  Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity Is Associated with Phosphorylation of Raptor by mTOR* , 2009, Journal of Biological Chemistry.

[47]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[48]  A. Chatterjee,et al.  Mitochondrial DNA mutations in human cancer , 2006, Oncogene.

[49]  B. Nashan mTOR Inhibition and Clinical Transplantation: Liver , 2017, Transplantation.

[50]  M. Rosner,et al.  mTOR phosphorylated at S2448 binds to raptor and rictor , 2008, Amino Acids.

[51]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.